Publications by authors named "Hilary Calvert"

Claim this Profile
H
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.
Andrew E Teschendorff, Shih-Han Lee, Allison Jones, Heidi Fiegl, Marie Kalwa, Hilary Calvert

Genome Med· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
Lee M Krug, Hedy L Kindler, Hilary Calvert, Christian Manegold, Anne S Tsao

Lancet Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Hilary Calvert, Chris Twelves, Malcolm Ranson, Ruth Plummer, Scott Fettner

Anticancer Drugs· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
Christophe Massard, Jane Margetts, Nadia Amellal, Yvette Drew, Ratislav Bahleda, Hilary Calvert

Invest New Drugs· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Ruth Plummer, Paul Lorigan, Neil Steven, Lucy Scott, Mark R Middleton, Hilary Calvert

Cancer Chemother Pharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
Lesley K Seymour, A Hilary Calvert, Marinus W Lobbezoo, Elizabeth A Eisenhauer, Giuseppe Giaccone

Eur J Cancer· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted agents: how to select the winners in preclinical and early clinical studies?
Rachel Goodwin, Giuseppe Giaccone, Hilary Calvert, Marinus Lobbezoo, Elizabeth A Eisenhauer

Eur J Cancer· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein.
Kappusamy Saravanan, Hannah C Barlow, Marion Barton, A Hilary Calvert, Bernard T Golding

J Med Chem· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.
Timothy A Yap, Laura Vidal, Jan Adam, Peter Stephens, James Spicer, Hilary Calvert

J Clin Oncol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
Martin D Forster, Nagahiro Saijo, Lesley Seymour, Hilary Calvert

Clin Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A monoclonal antibody for detection of folylpolyglutamate synthetase in paraffin embedded tissues.
Amy E Quinn, Michael Pinkney, Nigel H Piggott, Hilary Calvert, Ian D Milton

Hybridoma (Larchmt)· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
Leonard W Seymour, David R Ferry, David J Kerr, Daniel Rea, Maggie Whitlock, Hilary Calvert

Int J Oncol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.
Ignace Vergote, Hilary Calvert, Marek Kania, Christopher Kaiser, Annamaria Hayden Zimmermann

Eur J Cancer· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Ruth Plummer, Laura Vidal, Melanie Griffin, Mark Lesley, Johann de Bono, Hilary Calvert

Clin Cancer Res· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
Shivaani Kummar, James H Doroshow, Joseph E Tomaszewski, A Hilary Calvert, Marinus Lobbezoo

Eur J Cancer· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Ruth Plummer, Christopher Jones, Mark Middleton, Richard Wilson, Jeffrey Evans, Hilary Calvert

Clin Cancer Res· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).
Janet S Graham, Ruth Plummer, Candice McCoy, Kristin Kowal, Herbert Wiesinger, Hilary Calvert

Eur J Cancer· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential of PARP inhibitors in genetic breast and ovarian cancers.
Yvette Drew, Hilary Calvert

Ann N Y Acad Sci· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
A Hilary Calvert, Ruth Plummer

Clin Cancer Res· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of chemoresistance to alkylating agents in malignant glioma.
Jann N Sarkaria, Gaspar J Kitange, C David James, Ruth Plummer, Hilary Calvert

Clin Cancer Res· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
Christopher M Booth, A Hilary Calvert, Giuseppe Giaccone, Marinus W Lobbezoo, Lesley K Seymour

Eur J Cancer· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy.
Elizabeth Ruth Plummer, Hilary Calvert

Clin Cancer Res· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Markus Joerger, Alwin D R Huitema, Dick J Richel, Christian Dittrich, Nikolas Pavlidis, Hilary Calvert

Clin Cancer Res· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.
Ruth Plummer, Gerhardt Attard, Simon Pacey, Louise Li, Albiruni Razak, Hilary Calvert

Clin Cancer Res· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues.
Amy E Smith, Michael Pinkney, Nigel H Piggott, Hilary Calvert, Ian D Milton

Hybridoma (Larchmt)· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis